Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

(2020) Meng Yuan et al.   SCIENCE

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

(2020) Tyler N. Starr et al.   CELL

Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies

(2020) Bingfeng Liu et al.   Cellular & Molecular Immunology

SARS-CoV-2 vaccines in development

(2020) Florian Krammer   NATURE

Spike mutation D614G alters SARS-CoV-2 fitness

(2020) Jessica A. Plante et al.   NATURE

COVID-19-neutralizing antibodies predict disease severity and survival

(2020) Wilfredo F. Garcia-Beltran et al.   CELL

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

(2020) Erik Volz et al.   CELL

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

(2020) Drew Weissman et al.   Cell Host & Microbe

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

(2020) Xiancai Ma et al.   IMMUNITY

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

(2020) Lizhou Zhang et al.   Nature Communications